CN1723884A - 顺式－1，2－取代的二苯乙烯衍生物用于制备治疗或预防糖尿病的药物的用途 - Google Patents

顺式－1，2－取代的二苯乙烯衍生物用于制备治疗或预防糖尿病的药物的用途 Download PDF

Info

Publication number
CN1723884A
CN1723884A CNA2004100693745A CN200410069374A CN1723884A CN 1723884 A CN1723884 A CN 1723884A CN A2004100693745 A CNA2004100693745 A CN A2004100693745A CN 200410069374 A CN200410069374 A CN 200410069374A CN 1723884 A CN1723884 A CN 1723884A
Authority
CN
China
Prior art keywords
purposes
formula
medicine
cis
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2004100693745A
Other languages
English (en)
Inventor
康志云
吴祖泽
孙庄蓉
唐仲雄
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institute of Radiation Medicine of CAMMS
Original Assignee
Institute of Radiation Medicine of CAMMS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institute of Radiation Medicine of CAMMS filed Critical Institute of Radiation Medicine of CAMMS
Priority to CNA2004100693745A priority Critical patent/CN1723884A/zh
Priority to PCT/CN2005/001086 priority patent/WO2006007794A1/zh
Priority to EP05766919A priority patent/EP1801087B1/en
Priority to CN200580024419XA priority patent/CN1989090B/zh
Priority to US11/658,239 priority patent/US8039513B2/en
Priority to JP2007521774A priority patent/JP4991537B2/ja
Publication of CN1723884A publication Critical patent/CN1723884A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/32—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C07C235/34—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/32—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C07C235/36—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C39/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring
    • C07C39/23—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring polycyclic, containing six-membered aromatic rings and other rings, with unsaturation outside the aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/02—Ethers
    • C07C43/20—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring
    • C07C43/23—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring containing hydroxy or O-metal groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
    • C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/017—Esters of hydroxy compounds having the esterified hydroxy group bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/52—Esters of acyclic unsaturated carboxylic acids having the esterified carboxyl group bound to an acyclic carbon atom
    • C07C69/533—Monocarboxylic acid esters having only one carbon-to-carbon double bond
    • C07C69/54—Acrylic acid esters; Methacrylic acid esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/10—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/14—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/203—Monocyclic carbocyclic rings other than cyclohexane rings; Bicyclic carbocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/09—Geometrical isomers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Furan Compounds (AREA)

Abstract

本发明涉及顺式1，2－取代的二苯乙烯衍生物或其药学上可接受的盐、其糖苷或溶剂化物用于制备治疗或预防糖尿病或改善其并发症的药物的用途。

Description

顺式-1，2-取代的二苯乙烯衍生物用于制备 治疗或预防糖尿病的药物的用途
技术领域：
本发明涉及顺式-1，2-取代的二苯乙烯衍生物或其药学上可接受的盐、其糖苷或溶剂化物用于制备治疗或预防糖尿病及改善其并发症的药物的用途。
背景技术
糖尿病是一种全球性的临床常见的代谢性慢性疾病。近年来，随着经济的发展和人们饮食结构的改变，糖尿病的患病率正在世界范围内迅速升高。据统计，全球患者总数可达一亿两千多万，我国估计约有三千多万，多数为非胰岛素依赖型即II型糖尿病。可见糖尿病已成为继心血管、肿瘤之后的又一严重危害人们健康的严重疾病。
糖尿病的病程长，调治失当常有并发症发生，如慢性血管性并发症(包括脑血管障碍、缺血性心脏病)、糖尿病性肾病等。糖尿病并发症所致的死亡率也正在逐年增加。因此，对糖尿病及其并发症的防治成为全球医药工作者的重点研究课题。
目前临床应用的口服降血糖药物主要以西药为主。按其化学结构可分为：磺酰脲类、双胍类、苯丙氨酸类、噻唑烷二酮类、糖酯类。此外，还有正在研究开发中的1，2-二苯乙烯类化合物。据US6,410,596和CN1398838A报道，1，2-二苯乙烯类化合物存在于许多植物中，目前发现至少在21个科31个属的几十种植物中都存在此类化合物，同时还发现它们具有广泛的生理作用，如抗氧化作用、抗肿瘤作用、抗瘀血综合症作用、降血糖作用等。但是，具有上述这些作用的1，2-二苯乙烯类化合物的结构均为反式1，2-二苯乙烯的衍生物。关于顺式1，2-取代的二苯乙烯衍生物的生物活性，只有美国专利5,525,632中报道了风车子新碱(combrotastatin)及其衍生物具有抗肿瘤活性。
发明内容
本发明人经研究发现，顺式1，2-取代的二苯乙烯类化合物、其药学上可接受的盐、其糖苷或溶剂化物具有良好的降血糖等作用，因而可用于糖尿病及其并发症的治疗和预防。
因此，本发明涉及式I顺式1，2-取代的二苯乙烯化合物、其药学上可接受的盐、其糖苷或溶剂化物用于制备治疗或预防糖尿病或改善其并发症的药物的用途，
其中，
R1-R12可以相同或不相同，各自独立地为氢、羟基、C1-C6烷基、C1-C6烷氧基、C1-C6酯基、氨基、C1-C6烷氨基、C1-C6烷基磺酰基、磺酰氨基、磺酰脲基、胍基、羧基、C1-C6酰基、硝基、氰基、卤素、OM1、M2或SO2OM3基团，其中M1、M2、M3可以相同或不同，各自独立地代表氢或选自碱金属或碱土金属的阳离子或NH4 +，或为含糖的苷。
本发明的另一个方面涉及药物组合物，其中含有作为活性成分的式I顺式1，2-取代的二苯乙烯化合物、其药学上可接受的盐、其糖苷或溶剂化物以及一或多种药学上可接受的载体。
本发明的再一个方面涉及治疗或预防糖尿病及改善其并发症的方法，包括给予糖尿病患者治疗有效量的上述式I化合物。
在本发明的一个优选实施方案中，所述的式I化合物具有以下式II，式III和式IV结构：
Figure A20041006937400062
或
在本发明的另一个优选实施方案中，所述的糖苷为葡萄糖苷或甘露糖苷，或者，所述的溶剂化物为水合物。
本发明式I化合物可参考文献(Tetrahedron 2003，59，3315-3321)描述的方法制得。
根据本发明，顺式1，2-取代的二苯乙烯衍生物可按本领域常规的方法制成肠道或非肠道给药的制剂，如片剂、胶囊剂、颗粒剂、注射剂、栓剂、滴剂或贴剂等。
具体实施方式
下面实施例是对本发明的进一步详细说明但不意味着对本发明的任何限制。
实施例1
顺式-1-苯基-2-(3-甲氧基-4-羟基苯基)乙烯(式II化合物)的制备：
称取1.5克α-3-甲氧基-4-羟基苯基肉桂酸，置于100毫升配备有回流管的三口瓶中，在磁力搅拌下，加入7毫升喹啉和0.25克铜粉，电热功当量煲加热至210℃，并搅拌1小时，反应过程中有二氧化碳气体放出，发出轻微的***声。反应完毕后稍微冷却，加入20毫升乙酸乙酯，过滤后，用2N的盐酸洗涤反应液，水洗涤，无水MgSO4干燥，得到黄色固体。TCL(氯仿∶甲醇：9.5∶0.5)显示原料α-3-甲氧基-4-羟基苯基肉桂酸没有荧光，而脱羧后生成的产物二苯乙烯具有很强的荧光。
MS(FAB)m/z：M+ 226.0；
1H-NMR(DMSO)δ9.16(s 1H-OH)，3.84(s 3H-OCH3)，7.54(d 2H2，6-H)，6.78(d 1H 2-H)，7.37(t 2H α，β-H)，7.35，7.26，7.09(arom5H)。
实施例2
顺式-2-苯基-3-(3-羟基-4-甲氧基苯基)丙烯酸(式III化合物)的制备：
在250毫升的三口瓶中加入13.6克(0.1摩尔)苯乙酸，15.2克(0.1摩尔)异兰香素，12毫升(0.07摩尔)三乙胺，18毫升(0.18摩尔)乙酸酐，磁力搅拌，110℃油浴回流12小时，反应完毕后，冷却到室温，加入200毫升乙酸乙酯，用水洗涤到中性，无水硫酸钠干燥过夜，除去干燥剂，减压除去溶剂，加入无水***，析出白色固体7.55克，产率27.9％，熔点180-190℃。
MS(FAB)m/z M+270.0；
1H-NMR(DMSO)δ8.81(s 1H，-OH)，12.60(s 3H，-OCH3)，7.40，7.39，7.18.6.95(2-H)，6.72(s 1H，β-H)，3.72(s 3H，-OCH3)，7.40，7.39，7.18，6.95(arom 7H)。
实施例3
顺式2-苯基-3-(3-甲氧基-4-羟基苯基)丙烯酸(式IV化合物)的制备：
在250毫升的三口瓶中加入13.6克(0.1摩尔)苯乙酸，15.2克(0.1摩尔)香草醛，12毫升(0.07摩尔)三乙胺，18毫升(0.18摩尔)乙酸酐，磁力搅拌，110℃油浴回流12小时，反应完毕后，冷却到室温，加入200毫升乙酸乙酯，用水洗至中性，无水硫酸钠干燥过夜，除去干燥剂，减压除去溶剂，加入无水***，析出白色固体11.1克，产率40％，熔点200-210℃。
MS(FAB)m/z M+270.0；
1H-NMR(DMSO)δ8.92(s 1H，-OH)，12.73(s 1H，-COOH)，7.76(s 1H，2-H)，6.67(s 1H，β-H)，3.35(s，3H，OCH3)，(s 1H，β-H)，7.43，7.22，7.21，6.95(arom 7H).
实施例4本发明化合物的降糖活性
以反式1，2-二苯乙烯衍生物E2，即3，3’，5-三羟基-4’-甲氧基芪-3-O-β-D-葡糖苷(rhaponticin，参见CN 01120597.0)作为阳性对照药，对本发明化合物的降糖效果进行了初步评价。
实验选用雄性昆明小鼠(合格证：医动字D01-3023)，体重21-33克，禁食并自由摄取16小时后给药。对照药物或受试药物分别以二甲亚砜为溶剂按400mg或800mg/2.5ml/Kg配制灌胃，15分钟后口服葡萄糖2g/10ml/Kg。在1小时时断尾采血1滴，用美国强生集团理康公司稳捷基础型血糖监测仪，葡萄糖氧化酶法试纸测试血糖水平。对照组给予二甲亚砜2.5ml/Kg及葡萄糖2g/10ml/Kg灌胃。结果如表1所示：
表1.本发明化合物对高糖小鼠的降糖作用
  代号   剂量(mg/Kg)   动物数   给药后1小时血糖M±SD(mmol/L)
  DMSOE2式II化合物式III化合物式IV化合物 400800400400400   555555   9.50±1.069.14±1.907.02±1.01**7.62±1.59*7.30±0.68*8.20±0.99
*P＜0.05，**P＜0.01，与对照组比较，给予本发明化合物的给药组血糖下降。
由表中数据可见，本发明化合物能有效降低高血糖小鼠的血糖，说明其可用于治疗或预防糖尿病及改善其并发症。

Claims (5)

1.式I顺式1，2-取代二苯乙烯衍生物或其药学上可接受的盐、其糖苷或溶剂化物用于制备治疗或预防糖尿病或改善其并发症的药物的用途，
Figure A2004100693740002C1
式I
其中，
R1-R12可以相同或不相同，各自独立地为氢、羟基、C1-C6烷基、C1-C6烷氧基、C1-C6酯基、氨基、C1-C6烷氨基、C1-C6烷基磺酰基、磺酰氨基、磺酰脲基、胍基、羧基、C1-C6酰基、硝基、氰基、卤素、OM1、M2或SO2OM3基团，其中M1、M2、M3可以相同或不同，各自独立地代表氢或选自碱金属或碱土金属的阳离子或NH4 +，或为含糖的苷。
2.权利要求1的用途，其中的式I化合物具有以下结构：
Figure A2004100693740002C2
式II，
Figure A2004100693740002C3
式III或
Figure A2004100693740003C1
式IV。
3.权利要求1或2的用途，其中的糖苷为葡萄糖苷或甘露糖苷。
4.权利要求1或2的用途，其中的溶剂化物为水合物。
5.权利要求1或2的用途，其中的药物以片剂、胶囊、颗粒剂、贴剂、栓剂、滴剂或注射剂的形式存在。
CNA2004100693745A 2004-07-21 2004-07-21 顺式－1，2－取代的二苯乙烯衍生物用于制备治疗或预防糖尿病的药物的用途 Pending CN1723884A (zh)

Priority Applications (6)

Application Number Priority Date Filing Date Title
CNA2004100693745A CN1723884A (zh) 2004-07-21 2004-07-21 顺式－1，2－取代的二苯乙烯衍生物用于制备治疗或预防糖尿病的药物的用途
PCT/CN2005/001086 WO2006007794A1 (fr) 2004-07-21 2005-07-20 Derives de stilbene cis-1,2-substitues et utilisation de ceux-ci pour la preparation de medicaments servant au traitement ou a la prevention du diabete
EP05766919A EP1801087B1 (en) 2004-07-21 2005-07-20 Cis-1,2-substituted stilbene derivatives for treating and/or preventing diabetes
CN200580024419XA CN1989090B (zh) 2004-07-21 2005-07-20 顺式-1,2-取代的二苯乙烯衍生物及其用于制备治疗和/或预防糖尿病的药物的用途
US11/658,239 US8039513B2 (en) 2004-07-21 2005-07-20 Cis-1,2-substituted stilbene derivatives and their use in preparation of drugs for treatment and/or prevention of diabetes
JP2007521774A JP4991537B2 (ja) 2004-07-21 2005-07-20 シス−１，２−置換スチルベン誘導体、および糖尿病の治療および／または予防のための薬剤の製造におけるそれらの使用

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CNA2004100693745A CN1723884A (zh) 2004-07-21 2004-07-21 顺式－1，2－取代的二苯乙烯衍生物用于制备治疗或预防糖尿病的药物的用途

Publications (1)

Publication Number Publication Date
CN1723884A true CN1723884A (zh) 2006-01-25

Family

ID=35784879

Family Applications (2)

Application Number Title Priority Date Filing Date
CNA2004100693745A Pending CN1723884A (zh) 2004-07-21 2004-07-21 顺式－1，2－取代的二苯乙烯衍生物用于制备治疗或预防糖尿病的药物的用途
CN200580024419XA Expired - Fee Related CN1989090B (zh) 2004-07-21 2005-07-20 顺式-1,2-取代的二苯乙烯衍生物及其用于制备治疗和/或预防糖尿病的药物的用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN200580024419XA Expired - Fee Related CN1989090B (zh) 2004-07-21 2005-07-20 顺式-1,2-取代的二苯乙烯衍生物及其用于制备治疗和/或预防糖尿病的药物的用途

Country Status (5)

Country Link
US (1) US8039513B2 (zh)
EP (1) EP1801087B1 (zh)
JP (1) JP4991537B2 (zh)
CN (2) CN1723884A (zh)
WO (1) WO2006007794A1 (zh)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7939703B2 (en) 2007-12-03 2011-05-10 Technical Institute of Physics and Chemistry of Chinese Academy of Science Method for photocatalytic isomerization of 1,2-diphenylethylene analogues
CN105362282A (zh) * 2015-07-23 2016-03-02 黄冈师范学院 一种治疗糖尿病的活性物质及其制备方法和药物

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005069998A2 (en) * 2004-01-20 2005-08-04 Brigham Young University Technology Transfer Office Novel sirtuin activating compounds and methods for making the same
AU2010337825A1 (en) 2009-12-29 2012-07-05 Mapi Pharma Limited Intermediate compounds and processes for the preparation of tapentadol and related compounds
CN102584805B (zh) * 2011-12-07 2015-04-01 浙江农林大学 天然植物中一个活性成分的制备方法
CN117736099A (zh) * 2022-09-22 2024-03-22 中国科学院上海药物研究所 用于防治血管扩张性疾病的化合物及其制法和用途

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4996237A (en) * 1987-01-06 1991-02-26 Arizona Board Of Regents Combretastatin A-4
TW325458B (en) * 1993-09-08 1998-01-21 Ajinomoto Kk Stilbene derivatives and pharmaceutical compositions comprising the same for anti-cancer
US5731353A (en) * 1993-09-08 1998-03-24 Ajinomoto Co., Inc. Stilbene derivatives and pharmaceutical compositions containing them
JPH0959245A (ja) 1995-08-25 1997-03-04 Yamanouchi Pharmaceut Co Ltd Ｎ−（２−プロペノイル）グアニジン誘導体
FR2778337B1 (fr) 1998-05-05 2001-08-31 Inst Nat Sante Rech Med Antagonistes des ligands du recepteur des arylhydrocarbures
US6245814B1 (en) * 1998-05-08 2001-06-12 Calyx Therapeutics, Inc. Diphenylethylene compounds
GB9903403D0 (en) * 1999-02-16 1999-04-07 Angiogene Pharm Ltd Substituted stilbene compounds with vascular damaging activity
JP2000256259A (ja) * 1999-03-11 2000-09-19 Nippon Zoki Pharmaceut Co Ltd メイラード反応阻害剤
AU778767C (en) * 1999-05-18 2006-09-07 Theracos, Inc. Novel diphenylethylene compounds
GB9918912D0 (en) 1999-08-12 1999-10-13 Angiogene Pharm Ltd New stilbenes with vascular damaging activity
CN1224383C (zh) 1999-11-05 2005-10-26 中国人民解放军军事医学科学院放射医学研究所 一类新型降低血糖化合物
NZ520829A (en) 2000-02-04 2004-12-24 Calyx Therapeutics Inc Diphenylethylene compounds for treating diabetes and related conditions
GB0031263D0 (en) 2000-12-21 2001-01-31 Paterson Inst For Cancer Res Materials and methods for synthesizing stilbenes
WO2002050007A2 (en) 2000-12-21 2002-06-27 Cancer Research Technology Limited Substituted stilbenes, their reactions and anticancer activity
CN1398838A (zh) * 2001-07-26 2003-02-26 中国人民解放军军事医学科学院放射医学研究所 二苯乙烯类化合物制备以及它们在治疗和预防糖尿病中的应用
WO2003035008A2 (en) 2001-10-26 2003-05-01 Oxigene, Inc. Functionalized stilbene derivatives as improved vascular targeting agents

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7939703B2 (en) 2007-12-03 2011-05-10 Technical Institute of Physics and Chemistry of Chinese Academy of Science Method for photocatalytic isomerization of 1,2-diphenylethylene analogues
CN105362282A (zh) * 2015-07-23 2016-03-02 黄冈师范学院 一种治疗糖尿病的活性物质及其制备方法和药物

Also Published As

Publication number Publication date
US20090076114A1 (en) 2009-03-19
WO2006007794A1 (fr) 2006-01-26
JP2008506722A (ja) 2008-03-06
EP1801087B1 (en) 2012-08-29
EP1801087A4 (en) 2009-09-16
US8039513B2 (en) 2011-10-18
CN1989090B (zh) 2011-06-01
CN1989090A (zh) 2007-06-27
EP1801087A1 (en) 2007-06-27
JP4991537B2 (ja) 2012-08-01

Similar Documents

Publication Publication Date Title
CN1139929A (zh) 取代的3-亚芳基-7-氮杂羟吲哚化合物及其制备方法
CN107721959B (zh) 杨梅素衍生物及制备方法，及其在治疗结肠炎、防治结肠炎癌转化和治疗结直肠癌中的应用
CN108524482A (zh) 2-(取代苯氨基)苯甲酸类fto抑制剂治疗白血病的用途
CN102344481A (zh) 3-o-咖啡酰齐墩果烷型五环三萜类酯衍生物、其制备方法及应用
CN1989090B (zh) 顺式-1,2-取代的二苯乙烯衍生物及其用于制备治疗和/或预防糖尿病的药物的用途
CN101805285B (zh) 含烟酸姜黄素酯衍生物及其制造方法和用途
CN104892663B (zh) 以氨基三乙酸衍生物为配体的钒类配位化合物及制备方法与应用
CN111423438B (zh) 具有抗肿瘤活性的Eudistomins Y类衍生物及其制备方法和应用
CN1301987C (zh) 7－羧基－黄酮衍生物、其制备方法和应用
CN106748939B (zh) 一类新型溴酚氨基硫脲类化合物及其制备和药物与用途
JP6169978B2 (ja) スフィンゴイド塩基を含む抽出物の製造方法
US20090161561A1 (en) Method and system for determining characters of channels
CN116693521A (zh) 一种含色酮结构的噻唑烷二酮乙酯类化合物及其制备方法、药物组合物和应用
CN114426538B (zh) 一种小檗碱卡格列净衍生物及其制备方法和应用
CN1475488A (zh) 含氟异黄酮衍生物、制造方法及其用途
CN101974016A (zh) 酰胺类化合物及其制备方法和用途
CN104926804B (zh) 一类具有抗肿瘤作用的化合物、其制备方法和用途
WO2004080455A1 (ja) 抗菌剤と抗ガン剤
CN1049665A (zh) 羧基酰胺衍生物
JPH08295673A (ja) カルボスチリル誘導体ビスマス塩
CN104086529B (zh) 一种喹唑啉类衍生物、其制备方法及其用途
CN103965202B (zh) 二环稠合杂环化合物、其制备方法及用途
WO2015176542A1 (zh) N6-(1-(4-甲氧基苯基)乙基)-腺苷、其制备及用途
EP0293146A1 (en) Benzofuro [3,2-c] quinoline compounds
CN1475487A (zh) 含氟黄酮类化合物、制造方法及其用途

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication